Supplementary File 1: EZH2 Blockade and Doxorubicin Resistance in Breast Cancer

A 17.0 KB DOCX file authored by Xiaomin Wang and last updated on 2026-05-14. This supplementary document contains results and discussion from a study investigating EZH2 inhibition as a strategy to overcome doxorubicin resistance in breast cancer, including in vitro and in vivo findings.

Use Cases

• Analyzing the role of EZH2 in doxorubicin resistance based on the described transcriptomic profiling and pathway alterations.
• Investigating synergistic cytotoxicity of drug combinations based on the described in vitro cell viability assays.
• Studying mechanisms of DNA damage and repair suppression based on the described findings of γH2AX accumulation and pathway analysis.
• Evaluating nanoparticle delivery systems for chemotherapy based on the described pH-responsive liposomal system developed for in vivo use.

Strengths

• File is licensed under CC-BY-4.0, permitting open sharing and adaptation.
• Description provides specific methodological details, including cell models (DOX-resistant breast cancer), inhibitors used (tazemetostat, GSK126), and assays performed.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• The dataset is a single 17.0 KB DOCX file, indicating a very limited scope of raw data.

Provenance

Source

figshare

Collection Method

Likely contains supplementary results, figures, and discussion from the described research study involving in vitro assays, transcriptomic profiling, and in vivo experiments.

Time Range

null

Freshness

Last updated 2026-05-14 07:17:45; freshness should be verified.

Geography

null